Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL-A167 in Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT03848286Phase 2Completed
- Sponsor
- Kelun-Biotech
- Start
- Mar 2019
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tagitanlimab in nasopharyngeal carcinoma (NPC), sponsored by Kelun-Biotech. Started Mar 2019; status: completed.
02
Drugs
tagitanlimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03848286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03848286.